

Table SIII. Cost of the motivational interviewing (MI) intervention, healthcare services and psoriasis treatment and productivity loss

| Cost (€) | Study group (€) | | | | Control group (€) | | | | Between-group difference after the intervention (T3 + T4 (confidence interval), p-value |
|---|-----------------|---------------|---------------|---------------|-------------------|---------------|------------------------------------|-----------------------------------|---|
| | T1 | T3 | T4 | Mean (SD) | T1 | T3 | T4 | Mean (SD) | |
| <i>Total cost: MI intervention</i> | | | | | | | | | |
| General practitioner (consult + telephone) | 0 | 243 (65) | 0 | 0 | 0 | 130 (137) | 0 | 0 | 243 (227,254), p<0.001 |
| Dermatologist | 186 (158) | 152 (167) | 120 (115) | 231 (465) | 130 (137) | 100 (194) | 101 (131) | 44 (-47, 136), p=0.34 | |
| UVB treatment | 113 (142) | 47.5 (97) | 33 (73) | 248 (962) | 100 (194) | 59 (241) | 73 (131) | -105 (-189,-20), p=0.016 | |
| Hospital admittance due to psoriasis | 83 (216) | 33 (144) | 21 (164) | 119 (382) | 59 (241) | 106 (851) | 83.5 (201) | -104 (-216, 8), p=0.068 | |
| Allied healthcare ¹ | 977 (8,389) | 0 (0) | 55 (443) | 830 (6,881) | 106 (851) | 130 (501) | 0.00 (0.0) | -61 (-320,199), p=0.65 | |
| Other medical specialists ² | 307(601) | 158 (382) | 215 (474) | 276 (731) | 130 (501) | 49 (205) | 232 (626) | -4 (-338,330), p=0.98 | |
| Alternative health products | 37 (95) | 32 (80) | 20 (67) | 69 (357) | 49 (205) | 6 (24) | 32 (127) | -37 (-115, 41), p=0.35 | |
| Alternative treatment ³ | 14.5 (64) | 0.7 (6.3) | 0.06 (0.4) | 47 (189) | 6 (24) | 90 (260) | 6.8 (33) | -14 (-24, -3), p=0.011 | |
| Cost group 1 | 22 (71) | 37 (189) | 30 (107) | 57 (186) | 90 (260) | 674 (1,512) | 59 (157) | -118 (-220,-16), p=0.002 | |
| Prescription anti-PSO topical treatment (without hydrocortisone (HK)) | 1,746 (8,473) | 464 (634) | 526 (766) | 1,876 (7,904) | 674 (1,512) | 80 (92) | 579 (806) | -351 (-970, 268), p=0.27 | |
| Prescription topical medication with HK | 49 (84) | 58 (94) | 63 (86) | 51 (66) | 80 (92) | 31 (49) | 83 (144) | -37 (-98, 23), p=0.22 | |
| Systemic psoriasis treatment | 13 (24) | 41 (74) | 32 (54) | 8 (16) | 31 (49) | 15 (69) | 33 (50) | 9.8 (-22, 42), p=0.54 | |
| Biological treatment (DRG-based) | 11 (38) | 18 (56) | 14 (55) | 17 (66) | 15 (69) | 316 (1,170) | 21 (71) | -6 (-55, 43), p=0.81 | |
| OTC body lotion and emollients | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 113 (150) | 401 (1,306) | -799(-1499, -101), p=0.025 | |
| Cost group 2 | 90 (102) | 114 (88) | 119 (107) | 87 (135) | 113 (150) | 547 (1,183) | 102 (192) | 8.9 (-92, 110), p=0.86 | |
| <i>Total costs: Cost group 2</i> | 185 (169) | 228 (167) | 232 (163) | 239 (542) | 547 (1,183) | 657 (1,332) | 806 (-1518, -95), p=0.027 | | |
| <i>Total costs: Cost group 3</i> | 1,127 (3,133) | 1,632 (4,318) | 1,382 (3,795) | 1,986 (4,824) | 2,478 (5,380) | 1,952 (4,652) | -1048 (-3874, 1777), p=0.46 | | |

T1: baseline, T3: 3 months after CHT (after the MI intervention), T4: 6 months after CHT. Cost group 1: Use of primary and secondary healthcare; Cost group 2: (Pso-therapy, syst + topical, OTC and self-care products); Cost group 3: Productivity loss for employed patients. CI: confidence interval, 1 Euro (2012)=7.47 NOK, ¹as physiotherapist, manual therapist, chiropractor, psychologist, ²as rheumatologist, internist + assumed travel expenses, ³as healer, homeopath, podiatrist. Significant values are shown in bold. SD: standard deviation; DRG: Diagnosis-Related Group; OTC: over-the-counter; CHT: climate heliotherapy; UVB: ultraviolet B; PSO: psoriasis.